Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

Rhea-AI Summary

Immunocore Holdings plc (Nasdaq: IMCR) will report full year 2023 financial results on February 28, 2024. The Company aims to improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases through transformative immunomodulating medicines.

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 21 February 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report full year 2023 results, before the US markets open on Wednesday, February 28, 2024. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. ET (1:00 p.m. GMT) to discuss their financial results and provide a business and portfolio update.

Audio Webcast
The call will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay will also be made available for a limited time.

Conference Call Details:
Domestic (toll-free): 877-405-1239
International (toll): +1 201-389-0851

About Immunocore 
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom. 

CONTACT:  
Immunocore  
Sébastien Desprez, Head of Communications 
T: +44 (0) 7458030732 
E: sebastien.desprez@immunocore.com         
Follow on Twitter: @Immunocore  

Investor Relations   
Clayton Robertson, Head of Investor Relations 
T: +1 215-384-4781 
E: ir@immunocore.com 

FAQ

When will Immunocore report its full year 2023 financial results?

Immunocore will report its full year 2023 financial results on February 28, 2024.

What is the ticker symbol for Immunocore Holdings plc?

The ticker symbol for Immunocore Holdings plc is IMCR.

What does Immunocore focus on in terms of medical treatments?

Immunocore focuses on delivering transformative immunomodulating medicines to improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases.

Where can I access the live webcast of Immunocore's financial results announcement?

The live webcast of Immunocore's financial results announcement can be accessed by visiting the 'Events' section under 'News & Events' via the 'Investors' section of Immunocore's website at www.immunocore.com.

What time will the teleconference and webcast discussing Immunocore's financial results be held?

The teleconference and webcast discussing Immunocore's financial results will be held at 8:00 a.m. ET (1:00 p.m. GMT) on February 28, 2024.